Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 38, 2013, Pages 15247-15252

  Emmerich, Christoph H ^a   Ordureau, Alban ^a   Strickson, Sam ^a   Arthur, J Simon C ^a   Pedrioli, Patrick G A ^a   Komander, David ^b   Cohen, Philip ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

LUBAC; NF B; TNF Receptor Associated Factor 6; Ubc13

Indexed keywords

BINDING PROTEIN; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; LYSINE; METHIONINE; MYELOID DIFFERENTIATION FACTOR 88; POLYUBIQUITIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 BINDING PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 BINDING PROTEIN 3; UBIQUITIN; UNCLASSIFIED DRUG; ANAZOLENE SODIUM; CARRIER PROTEIN; FUCHSINE; IKBKG PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK4 PROTEIN, HUMAN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MULTIPROTEIN COMPLEX; PRIMER DNA; RNF31 PROTEIN, HUMAN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CATALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; C57BL MOUSE; ESCHERICHIA COLI; FIBROBLAST; GENE TARGETING; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; IMMUNOPRECIPITATION; INNATE IMMUNITY; MASS SPECTROMETRY; METABOLISM;

ANIMALS; CARRIER PROTEINS; DNA PRIMERS; ESCHERICHIA COLI; FIBROBLASTS; GENE KNOCK-IN TECHNIQUES; HEK293 CELLS; HUMANS; I-KAPPA B KINASE; IMMUNITY, INNATE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LYSINE; MAP KINASE KINASE KINASES; MASS SPECTROMETRY; METHIONINE; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; MYELOID DIFFERENTIATION FACTOR 88; POLYUBIQUITIN; RNA, SMALL INTERFERING; ROSANILINE DYES; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 84884345970     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314715110     Document Type: Article

References (41)

1. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10(11):760-774.
2. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169-181.
3. Mitsudomi T, et al.; West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11(2):121-128.
4. Mok TS, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957.
5. Rosell R, Viteri S, Molina MA, Benlloch S, Taron M (2010) Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 22(2):112-120.
6. Yun CH, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105(6):2070-2075.
7. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci USA 106(51): 21608-21613.
8. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6): 1137-1149.
9. Yun CH, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217-227.
10. Shan Y, et al. (2012) Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149(4):860-870.
11. Carey KD, et al. (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66(16):8163-8171.
12. Wang Z, et al. (2011) Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat Struct Mol Biol 18(12):1388-1393.
13. Thiel KW, Carpenter G (2007) Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci USA 104(49): 19238-19243.
14. Qiu C, et al. (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16(3):460-467.
15. Blair JA, et al. (2007) Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 3(4):229-238.
16. Gajiwala KS, et al. (2013) Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21(2):209-219.
17. Sogabe S, et al. (2012) Structure-based approach for the discovery of Pyrrolo[3,2d] pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Medicinal Chemistry Letters 4:201-205.
18. Jorissen RN, et al. (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284(1):31-53.
19. Fanger BO, Stephens JE, Staros JV (1989) High-yield trapping of EGF-induced receptor dimers by chemical cross-linking. FASEB J 3(1):71-75.
20. Mohammadi M, et al. (1993) Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. Biochemistry 32(34):8742-8748.
21. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306-13311.
22. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73.
23. Tzahar E, et al. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16(10):5276-5287.
24. Rusnak DW, et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1(2):85-94.
25. Wood ER, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64(18):6652-6659.
26. Li D, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702-4711.
27. Gilmer TM, et al. (2008) Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 68(2): 571-579.
28. Zhou W, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462(7276):1070-1074.
29. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687): 1163-1167.
30. Gao SP, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117(12):3846-3856.
31. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117-1134.
32. Shtiegman K, et al. (2007) Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 26(49):6968-6978.
33. Endres NF, Engel K, Das R, Kovacs E, Kuriyan J (2011) Regulation of the catalytic activity of the EGF receptor. Curr Opin Struct Biol 21(6):777-784.
34. Endres NF, et al. (2013) Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152(3):543-556.
35. Ladanyi M, Pao W (2008) Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond. Mod Pathol 21(Suppl 2):S16-S22.
36. Takezawa K, et al. (2012) HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2(10):922-933.
37. Jeng HH, Taylor LJ, Bar-Sagi D (2012) Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Commun 3:1168.
38. Young A, Lou D, McCormick F (2013) Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 3(1):112-123.
39. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymology, ed Carter CW, Jr (Academic, New York), pp 307-326.
40. Schröder GF, Levitt M, Brunger AT (2010) Super-resolution biomolecular crystallography with low-resolution data. Nature 464(7292):1218-1222.
41. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66(Pt 4):486-501.